Dr. Bauml Discusses Immunotherapy Agents in Head and Neck Cancer

Video

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses immunotherapy agents in head and neck cancer.

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses immunotherapy agents in head and neck cancer.

Related Videos
Rohan Garje, MD, chief, Genitourinary Medical Oncology, Baptist Health Miami Cancer Institute
Changchun Deng, MD, PhD, associate professor, hematology/oncology, University Hospitals Seidman Cancer Center; member, Immune Oncology Program, Case Comprehensive Cancer Center
Jaime R. Merchán, MD
Erin Frances Cobain, MD
Mark D. Tyson, II, MD, MPH
Michael Iglesia, MD, PhD
Sundar Jagannath, MBBS
Jonathan E. Rosenberg, MD
Núria Agustí Garcia, MD
Erin Frances Cobain, MD
Related Content
Marjorie Green, MD

Frontline Pembrolizumab Plus Trastuzumab/Chemo Meets OS End Point in HER2+ Gastric/GEJ Cancer

May 1st 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
stock.adobe.com

Eftilagimod Alpha Plus Pembrolizumab Elicits Early Efficacy Signals in Metastatic HNSCC

April 24th 2024
Article
Marvels in Medicine: Allison Talks Everything from Advances in Immunotherapy to Jamming With Willie Nelson

Marvels in Medicine: Allison Talks Everything from Advances in Immunotherapy to Jamming With Willie Nelson

November 22nd 2021
Podcast
Jameel Muzaffar, MD

Tivumecirnon Plus Pembrolizumab Shows Activity in Checkpoint Inhibitor–Exposed Recurrent/Metastatic HNSCC

April 21st 2024
Article
Eric S. Christenson, MD, assistant professor, oncology, Johns Hopkins Medicine

Early Data With Copanlisib/Nivolumab Combo Support Further Exploration in MSS CRC

April 18th 2024
Article